• "One Lab, Two Firms, Many Possibilities: On R&D Outsourcing in the Biopharmaceutical Industry" (Journal of Health Economics, 2019)

• "One Lab, Two Firms, Many Possibilities: On R&D Outsourcing in the Biopharmaceutical Industry" (Health Economics, 2019)

we aim in particular at understanding how the latter may explain the distribution of profits across the innovators and the drug manufacturers - and ultimately the structure of the industry.

• "Investment timing and vertical relationship" (See also the Slides)

• "Dynamic competition and intellectual property rights in a model of product development" (JEDC, 2019)

published in Health Economics in 2019, we aim in particular at understanding how the latter may explain the distribution of profits across the innovators and the drug manufacturers - and ultimately the structure of the industry.

R&D in the pharmaceutical industry

Vaccine

for which the slides are available

Within this context where firms investment timing depends upon the nature of their competition, we are also investigating the question of innovation protection in

• "When should a winner take all, or pay some? Innovation and imitation incentives in a dynamic duopoly"

R&D in the pharmaceutical industry

Vaccine

• "Investment timing and vertical relationship" (See also the Slides)

• "One Lab, Two Firms, Many Possibilities: On R&D Outsourcing in the Biopharmaceutical Industry"

With Bruno Versaevel, we are investigating for several years the R&D processes in the pharmaceutical industry. In

• "Investment timing and vertical relationship"

we aim in particular at understanding how the latter may explain the distribution of profits across the innovators and the drug manufacturers - and ultimately the structure of the industry.

Together with Richard Ruble, we wrote a contribution on that subject which has been published in IJIO in 2014:

Within this context where firms investment timing depends upon the nature of their competition, we are investigating the question of innovation protection in

• "Innovation and imitation incentives in dynamic duopoly"

The vaccine industry is very peculiar in that, by contrast to a drug, a vaccine cannot be produced by simple imitation. Its production requires very specific equipment and is thus, as such, a risky investment.

Another line of research we share with Bruno consists in studying the the impact of the industry structure upon the investment timing - and ultimately, the date at which drugs or vaccines become available. Together with Richard Ruble, we wrote a contribution that was published in IJIO in 2014:

With Bruno Versaevel, we are investigating for several years the R&D processes in the pharmaceutical industry. We aim in particular at understanding how the latter may explain the distribution of profits across the innovators and the drug manufacturers - and ultimately the structure of the industry.

The vaccine industry is very peculiar in that, by contrast to a drug, a vaccine cannot be produced by simple imitation. Its production requires very specific equipment and is thus, as such, a risky investment. Together with Richard Ruble, we study the impact of the industry structure upon the investment timing - and ultimately, the date at which vaccines become available. This gave rise to a contribution in IJIO:

• "Investment timing and vertical relationship"

We are currently investigating in a similar context the question of innovation protection.

Drug and Vaccine industry

Together, we have been working on how to model mental disorders. This gave rise to the note in BBS:

• "Latent Variables and the Network Perspective: Commentary on Cramer and alii,"

which is joint with Catherine Belzung, Vincent Camus and Mael Lemoine.

• "Latent Variables and the Network Perspective: Commentary on Cramer and alii,"

\\

\\

• "Latent Variables and the Network Perspective: Commentary on Cramer and alii"

With Catherine Belzung, we also came up with a formal model of the HPA-Axis, which is at the core of stress regulation:

• "The Design of New Antidepressants: can Formal Models help? A First Attempt using a Model of the Hippocampal Control over the HPA-axis based on a Review from the Literature"

According the WHO, major depression is about to become globally the most prevalent health disorder. Equipped with a better knowledge of how mental disorders are actually understood in the broad field of neuroscience, I hope to be able to come up with more relevant models to tackle this very serious public health problem.

Mental Health and Pharmacology

Together, we have been working on how to model mental disorders. This gave rise to the note:

• "Latent Variables and the Network Perspective: Commentary on Cramer and alii"

which is joint with Catherine Belzung, Vincent Camus and Mael Lemoine.

In the process of taking part to various initiatives that aim at inter-disciplinary dialogue, I came to know several researchers in the filed of Mental Health, gathered around Catherine Belzung.

Together, we have been working on how to model mental disorders. This gave rise to the comment:

which is joint with Catherine Belzung, and Mael Lemoine?.